Priveterra Acquisition Corp. II (PMGM)
| Previous close | 11.05 |
| Open | 11.09 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.09 - 11.09 |
| 52-week range | 10.42 - 11.21 |
| Volume | |
| Avg. volume | 178 |
| Market cap | 97.836M |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | 52.81 |
| EPS (TTM) | 0.21 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
IRVINE, Calif., May 03, 2024--Priveterra Acquisition Corp. II (NASDAQ: PMGMU, PMGM, PMGMW) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasda
GlobeNewswireAEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (
Business WirePriveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.
FORT LAUDERDALE, Fla., July 21, 2023--Priveterra Acquisition Corp. (Nasdaq: PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive t
